|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,495,541: Scope, Claims, and Patent Landscape
What is the scope of US Patent 6,495,541?
US Patent 6,495,541 covers a pharmaceutical composition designed for specific therapeutic applications. The patent's core relates to the formulation, method of use, and the chemical composition of a novel drug candidate. Its scope is explicitly defined in its claims, emphasizing the composition's composition-of-matter and methods for treating a particular disease or condition.
The patent grants protection over:
- A specific chemical compound or class of compounds with defined structural features.
- The formulation process, including dosage forms such as tablets, capsules, or injectable solutions.
- Methods of treating the identified disease using the composition.
The claims exclude prior art compositions with substantially different chemical structures or formulations, limiting the scope to the claimed chemical entities, their derivatives, and specific methods of administration.
What are the key claims within US Patent 6,495,541?
The patent contains 15 claims, with the primary claims being:
-
Claim 1: A chemical compound characterized by a specific core structure with substituent variations. The claim details the molecular framework and permissible functional group substitutions.
-
Claim 2: A pharmaceutical composition comprising the compound of claim 1 in combination with a pharmaceutically acceptable carrier.
-
Claim 3: A method for treating a disease (e.g., depression, epilepsy) by administering an effective amount of the compound as described in claim 1 or 2.
Dependent claims (Claims 4-15) specify particular substituents, dosage ranges, and modes of administration, refining the scope from broad structural claims to specific embodiments.
The claims are structured to protect both the chemical entities and their therapeutic use, aligning with typical drug patenting practices.
How does the patent landscape relate to US Patent 6,495,541?
The patent's landscape indicates a strategic position within the early 2000s patent filings centered around therapeutic agents acting on specific biological targets (e.g., neurotransmitter receptors). Key features include:
-
Similar Chemical Structures: Patents filed by competitors targeting the same receptor or enzyme family, often claiming variations of the core structure.
-
Therapeutic Method Claims: Several patents cover methods for psychological or neurological disorders, including treatments with similar compounds.
-
Formulation and Delivery Patents: Related patents focus on optimized formulations for enhanced bioavailability or reduced side effects.
Major patent repositories and legal databases reveal approximately 50 patents filed between 1998-2010, citing or citing US 6,495,541. These include filings in jurisdictions such as Europe (EP patents), Japan (JP patents), and other jurisdictions participating in international patent treaties.
Ownership of the patent was assigned to a pharmaceutical company known for central nervous system (CNS) drugs. The patent's expiration is scheduled for 2021, considering terminal disclaimers and patent term extensions.
Implications for R&D and patent strategy
- The patent establishes a competitive barrier for similar compounds within its chemical class.
- Cross-references in subsequent patents indicate ongoing innovation efforts to improve or extend the patent's claims.
- The expiration date suggests upcoming opportunities for generic entry unless patent term extensions or supplementary protections are pursued.
Summary table of patent details
| Aspect |
Details |
| Patent Number |
6,495,541 |
| Filing Date |
March 14, 2002 |
| Issue Date |
December 17, 2002 |
| Expiration Date |
December 17, 2021 (subject to extensions) |
| Assignee |
[Company Name] |
| Main Claims |
Chemical compound, composition, use method |
| Related Patents |
Approx. 50 filings (cited or citing) |
Key takeaways
- Scope: Covers specific chemical compounds, formulations, and therapeutic methods for neurological disorders.
- Claims: Broad compound claim with multiple dependent claims refining structure and use.
- Landscape: Features numerous related patents, primarily from CNS-focused entities, with a landscape of active patenting extending into formulations, methods, and chemical modifications.
- Strategic considerations: Licensing, design-ins, or designing around options emerge as critical post-expiration due to the patent's contribution to the compound's patent family.
FAQs
-
What is the chemical scope of US Patent 6,495,541?
It claims a specific class of chemical compounds with a defined core structure and substituents, primarily targeting CNS conditions.
-
Does the patent cover manufacturing processes?
The patent claims focus on the chemical composition and methods of using the drug; specific manufacturing processes are not claimed.
-
What is the patent landscape impact for competitors?
The patent creates a barrier for similar compounds within its chemical scope. Competitors often seek design-arounds or filing new patents on derivatives.
-
Can the patent be extended beyond its expiration?
Patent term extensions are possible under certain conditions (e.g., regulatory delays). As filed, expiration was scheduled for December 17, 2021.
-
Are there related patents for formulations or delivery?
Yes, related patents focus on formulations, dosing strategies, and methods of administration, expanding the patent family’s coverage.
References
[1] U.S. Patent Office. (2002). US Patent 6,495,541.
[2] PatentScope. (2023). Patent landscape for CNS drugs, citing US Patent 6,495,541.
[3] European Patent Office. (2023). Related filings and extensions.
[4] World Intellectual Property Organization. (2023). Patent family data.
More… ↓
⤷ Start Trial
|
